First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
François Anna, Elodie Bôle‐Richard, Joël LeMaoult, Marie Escande, Martin Lecomte, Jean-Marie Certoux, Philippe Souque, Francine Garnache, Olivier Adotévi, Pierre Langlade‐Demoyen, Maria Loustau, Julien Caumartin
Abstract
Background CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microenvironment sometimes caused by the tumorous expression of immune checkpoints (ICPs) such as HLA-G. Indeed, HLA-G is remarkable because it is both a potent ICP and a TSA. HLA-G tumor expression causes immune escape by impairing innate and adaptive immune responses and by inducing a suppressive microenvironment. Yet, to date, no immunotherapy targets it. Methods We have developed two anti-HLA-G third-generation CARs based on new anti-HLA-G monoclonal antibodies. Results Anti-HLA-G CAR-T cells were specific for immunosuppressive HLA-G isoforms. HLA-G-activated CAR-T cells polarized toward T helper 1, and became cytotoxic against HLA-G + tumor cells. In vivo, anti-HLA-G CAR-T cells were able to control and eliminate HLA-G + tumor cells. The interaction of tumor-HLA-G with interleukin (IL)T2-expressing T cells is known to result in effector T cell functional inhibition, but anti-HLA-G CAR-T cells were insensitive to this inhibition and still exerted their function even when expressing ILT2. Lastly, we show that anti-HLA-G CAR-T cells differentiated into long-term memory effector cells, and seemed not to lose function even after repeated stimulation by HLA-G-expressing tumor cells. Conclusion We report for the first time that HLA-G, which is both a TSA and an ICP, constitutes a valid target for CAR-T cell therapy to specifically target and eliminate both tumor cells and HLA-G + suppressive cells.